Cargando…
Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections
Drug-resistant pathogens have gained a foothold especially in the most vulnerable patient populations, hospitalized and immunocompromised individuals. Furthermore, extended-spectrum β-lactamase and carbapenemase-producing organisms are finding their way even into the community, with patients present...
Autor principal: | Skalweit, Marion J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461093/ https://www.ncbi.nlm.nih.gov/pubmed/26082619 http://dx.doi.org/10.2147/DDDT.S61436 |
Ejemplares similares
-
Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
por: Goodlet, Kellie J, et al.
Publicado: (2016) -
Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections
por: Giancola, Stephanie E, et al.
Publicado: (2016) -
Ceftolozane/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy
por: Escolà-Vergé, Laura, et al.
Publicado: (2019) -
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam
por: Popejoy, Myra W., et al.
Publicado: (2017) -
Ceftolozane/Tazobactam In-Vitro Activity against Clinical Isolates from Complicated Intra-Abdominal Infection Patients in Three Indonesian Referral Hospitals
por: Karuniawati, Anis, et al.
Publicado: (2022)